Skip to main content

Nixon Peabody LLP

  • People
  • Capabilities
  • Insights
  • About
Trending Topics
    • People
    • Capabilities
    • Insights
    • About
    • Locations
    • Events
    • Careers
    • Alumni
    Practices

    View All

    • Affordable Housing
    • Community Development Finance
    • Corporate & Finance
    • Cybersecurity & Privacy
    • Entertainment & Media
    • Environmental
    • Franchising & Distribution
    • Government Investigations & White Collar Defense
    • Healthcare
    • Intellectual Property
    • International Services
    • Labor, Employment, and Benefits
    • Litigation
    • Private Wealth & Advisory
    • Project Finance
    • Public Finance
    • Real Estate
    • Regulatory & Government Relations
    Industries

    View All

    • Aviation
    • Cannabis
    • Consumer
    • Energy
    • Financial Services
    • Healthcare
    • Higher Education
    • Infrastructure
    • Manufacturing
    • Nonprofit Organizations
    • Real Estate
    • Sports & Stadiums
    • Technology
    Value-Added Services

    View All

    • Alternative Fee Arrangements

      Developing innovative pricing structures and alternative fee agreement models that deliver additional value for our clients.

    • Continuing Education

      Advancing professional knowledge and offering credits for attorneys, staff and other professionals.

    • Crisis Advisory

      Helping clients respond correctly when a crisis occurs.

    • DEI Strategic Services

      Providing our clients with legal, strategic, and practical advice to make transformational changes in their organizations.

    • eDiscovery

      Leveraging law and technology to deliver sound solutions.

    • Environmental, Social, and Governance (ESG)

      We help clients create positive return on investments in people, products, and the planet.

    • Global Services

      Delivering seamless service through partnerships across the globe.

    • Innovation

      Leveraging leading-edge technology to guide change and create seamless, collaborative experiences for clients and attorneys.

    • IPED

      Industry-leading conferences focused on affordable housing, tax credits, and more.

    • Legal Project Management

      Providing actionable information to support strategic decision-making.

    • Legally Green

      Teaming with clients to advance sustainable projects, mitigate the effects of climate change, and protect our planet.

    • Nixon Peabody Trust Company

      Offering a range of investment management and fiduciary services.

    • NP Capital Connector

      Bringing together companies and investors for tomorrow’s new deals.

    • NP Second Opinion

      Offering fresh insights on cases that are delayed, over budget, or off-target from the desired resolution.

    • NP Trial

      Courtroom-ready lawyers who can resolve disputes early on clients’ terms or prevail at trial before a judge or jury.

    • Social Impact

      Creating positive impact in our communities through increasing equity, access, and opportunity.

    • Women in Dealmaking

      We provide strategic counsel on complex corporate transactions and unite dynamic women in the dealmaking arena.

    1. Home
    2. Insights
    3. Alerts
    4. An overview of funding mechanisms for emerging companies

      Alerts

    Alert / Emerging Companies

    An overview of funding mechanisms for emerging companies

    July 26, 2024

    LinkedInX (Twitter)EmailCopy URL

    By Allan Cohen, Jason Chimon and Marissa Espinoza Icochea

    Convertible notes versus SAFEs—which mechanisms are preferred for emerging companies to raise capital from investors?

    What’s the impact?

    • In the “seed funding” stage, the most common mechanisms through which emerging companies raise funds are convertible notes and simple agreements for future equity (SAFEs).
    • Convertible notes and SAFEs delay the valuation discussion since there isn’t a valuation upon issuance of the note or SAFE.
    • A company should create a business plan and budget and raise sufficient funds to get it to its next inflection point, when it can then go out and raise additional funds for a more developed company on better terms.

    DOWNLOAD

    Funding mechanisms for emerging companies (PDF)

    One of the challenges that emerging companies face is how—and via what mechanism—to raise capital to fuel growth. In the early stages, companies may be self-funded or raise capital from friends and family or other angel investors, through business incubators, or through various state programs. In this “seed funding” stage, convertible notes and simple agreements for future equity (SAFEs) are the most common mechanisms used to raise funds.

    In this article, we aim to give a broad overview of the two instruments and discuss some factors to consider when deciding which form of investment best suits the company’s needs. Stay tuned for future articles, where we plan to delve into the nitty-gritty of convertible instruments, along with insights into the host of other issues early-stage companies might encounter.

    What are convertible notes?

    Convertible notes are considered a debt security. They can be issued individually to investors or as part of a series of notes to multiple investors. Like any debt security, they have a maturity date, typically at least one to two years from the date of issuance. Interest rates are often low relative to a bank loan, as early-stage investors with their priorities straight should be more interested in conversion into equity than earning interest. Specifically, convertible notes require the conversion of the principal of the note plus the accrued interest at the time of a “qualified” equity financing by the company. If such financing does not occur by the maturity date, the investor typically has the option to call the loan or convert it into common stock of the company. It’s common to see either a discount or a cap in a note, meaning that when the note converts at the time of a qualified financing of the company, it converts either at a discounted price relative to the new investors (we see a 20% discount most frequently) or with an assumed “valuation cap” rather than the actual valuation used for the financing. Notes may also convert upon a sale of the company.

    For example:

    The note principal plus interest = $1 million. Say there is either a $5 million cap or a 20% discount.

    Next, assume the Company has 10 million shares outstanding at the time of a qualified financing. For simplicity’s sake, we assume the valuation cap is ‘pre-money’ (a bit of nitty-gritty to save for a rainy day), so these 10 million shares do not include any shares the investor receives when the note converts. Finally, let’s say the company’s capital raise is at a $10 million valuation and a price per share of $1.

    • With the cap, the note converts to 2 million shares because a valuation cap of $5 million is used rather than $10 million ($1 million in principal + interest/$5 million valuation = 20% of the Company’s 10 million shares or 2 million shares)
    • With the discount, the note converts to 1.25 million shares because a price per share of $.80 is used rather than $1.00 ($1 million in principal + interest/$.80 = 1.25 million shares)
    • With neither, the note would convert to 1 million shares ($1 million in principal + interest/$1.00 = 1 million shares)

    What is a SAFE?

    Unlike a convertible note, a SAFE is not considered a debt security but an agreement for the company to issue equity to the investor in the future. It is important to note that a SAFE is still a security and subject to federal and state securities laws. Since a SAFE is not a loan, there is no interest and no maturity date. SAFEs will convert into equity if the company closes a qualified financing. Like notes, the rate of conversion depends on whether there is a valuation cap or discount. Since SAFEs are not debt, SAFEs are paid after creditors but prior to common stock. Because of this, and because SAFEs do not accrue interest, they are viewed as more favorable to the company.

    Convertible notes versus SAFEs—Which is best for my company?

    Both notes and SAFEs delay the valuation discussion since there isn’t a valuation upon issuance of the note or SAFE (although valuation may loosely be discussed if a valuation cap is to be agreed to). Delaying agreement on a valuation may provide emerging companies with more flexibility to keep the exercise price for options (based on the fair market value of the underlying stock) low, thereby making options more valuable as a tool to better attract talent. In addition, both convertible notes and SAFEs typically don’t include a change to the board of directors beyond a significant holder being a board observer, and the holders will not be considered shareholders with voting or other shareholder rights.

    Still, SAFEs offer a few additional advantages to the company relative to convertible notes. They do not accrue interest or have a maturity date, and because SAFEs are not debt, their holders are not creditors. SAFEs also benefit from having a few well-understood industry forms, which could help streamline negotiations over notes. As a result, in all cases, SAFEs are the preferred mechanism for companies. Of course, at the end of the day, the investor may insist on a convertible note, and a company’s preference for a SAFE is only as good as the SAFE’s ability to attract investors.

    When to seek investments and how much

    The decision to seek investments comes down to when outside capital would accelerate company growth and is largely a business decision. All emerging companies require cash at various points in order to grow. However, a company should create a business plan and budget and raise sufficient funds (perhaps building in a cushion) to get it to its next inflection point, when it can then go out and raise additional funds for a more developed company on better terms.

    Practices

    Emerging CompaniesCorporate & FinanceMergers, Acquisitions, and Corporate Transactions Securities & Capital Markets

    Insights And Happenings

    • Alert

      FAQ: Recent SEC Form 13F enforcement actions

      Oct 29, 2024
    • Press Release

      Nixon Peabody advises fertility company ZyMōt Fertility in sale to CooperSurgical

      Aug 8, 2024
    • Article

      “Build with Nixon Peabody”: Startup and VC outlook for 2024

      May 14, 2024
    The foregoing has been prepared for the general information of clients and friends of the firm. It is not meant to provide legal advice with respect to any specific matter and should not be acted upon without professional counsel. If you have any questions or require any further information regarding these or other related matters, please contact your regular Nixon Peabody LLP representative. This material may be considered advertising under certain rules of professional conduct.

    Subscribe to stay informed of the latest legal news, alerts, and business trends.Subscribe

    • People
    • Capabilities
    • Insights
    • About
    • Locations
    • Events
    • Careers
    • Alumni
    • Cookie Preferences
    • Privacy Policy
    • Terms of Use
    • Accessibility Statement
    • Statement of Client Rights
    • Purchase Order Terms & Conditions
    • Nixon Peabody International LLC
    • PAL
    © 2025 Nixon Peabody. All rights reserved